You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Sciwind Biosciences (Hangzhou Sciwind Biosciences Co., Ltd.) is a commercial-stage biopharmaceutical company headquartered in Hangzhou, China, with a US office in San Ramon, California, focused on discovering, developing, and delivering innovative therapeutics for weight management and metabolic disease.
Nocion Therapeutics is a clinical-stage biopharmaceutical company discovering and developing a novel class of biologically selective charged sodium channel (NaV) blockers designed to selectively silence overactive sensory neurons to relieve chronic cough, pain, itch, and inflammation.
Braveheart Bio is a late clinical-stage biopharmaceutical company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiac conditions. Its lead candidate, BHB-1893, is a selective cardiac myosin inhibitor (licensed as HRS-1893 from Hengrui Pharma) designed to reduce excessive heart-muscle contraction and improve…
Totus Medicines is a biopharmaceutical company developing precision oral medicines against historically "undruggable" disease targets. The company's OmniDEL discovery platform screens targets in their normal cellular environment to identify potent, selective covalent small molecules, drawing on precedents like penicillin and AZT.
Seismic Therapeutic is a clinical-stage biopharmaceutical company developing transformative biologic medicines for autoimmune and inflammatory diseases. The company pairs structural biology with machine learning through its proprietary IMPACT platform to design multi-functional antibodies and Immunoglobulin Sculpting (IgSc) enzymes across…
Granata Bio is a reproductive-health biopharmaceutical company founded in 2018 and headquartered in the United States, focused on expanding access to fertility and IVF therapeutics across North America.
ArriVent BioPharma (NASDAQ: AVBP) is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines for the treatment of cancer.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapies for underserved areas of medical need. Leveraging a proprietary integrin drug discovery and delivery platform, its lead program PLN-101095 is a dual-selective avb8/avb1 integrin inhibitor being evaluated in the…
Aer Therapeutics is a clinical-stage biopharmaceutical company based in the Research Triangle Park / Raleigh area of North Carolina, developing novel treatments for muco-obstructive lung diseases such as COPD, asthma, cystic fibrosis, and non-CF bronchiectasis. A spinout from Dr.
kechowpharma — Kechow Pharma (Shanghai Kezhou Pharmaceutical Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Shanghai's Zhangjiang High-Tech Park.
Ark Biopharmaceutical (爱科百发, Ark Biosciences) is a Shanghai-based clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for respiratory diseases and pediatric conditions.
Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule and biologic therapeutics for autoimmune, inflammatory, and oncology indications. The company targets upstream immune signaling mechanisms to prevent pathological inflammation rather than only suppressing downstream responses, advancing a pipeline of…
Shanghai Vitalgen BioPharma Co., Ltd. (Vitalgen), founded in March 2020 and headquartered in Shanghai, China, translates cutting-edge gene delivery and gene editing techniques into clinically effective treatments for patients with unmet medical needs.
Metsera is a clinical-stage biopharmaceutical company developing injectable and oral therapies for obesity and metabolic diseases, backed by GV and the SoftBank Vision Fund. As of this enrichment pass its corporate domain (metsera.com) issues a 301 redirect to pfizer.com, consistent with Metsera's acquisition by Pfizer.
Forty Seven, Inc. was a clinical-stage immuno-oncology biopharmaceutical company developing therapies that target cancer immune-evasion pathways, based on technology licensed from Stanford University.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
Axcelius I/II is a biopharmaceutical company-creation vehicle backed by Canaan Partners, formed to found and incubate drug-development companies pursuing treatments for cancer, rare diseases, and neurodegenerative disorders.
Barinthus Biotherapeutics plc (Nasdaq: BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapies designed to guide and reprogram T cells to overcome autoimmunity, inflammatory disease, chronic viral infection, and cancer.
Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to transforming care for patients with inflammatory diseases such as asthma and COPD.